Do not publish directly or indirectly in the United States, Canada, Australia
Lunel, 5 July 2018
SUCCESS OF BIO-UV GROUP INITIAL PUBLIC OFFERING ON EURONEXT GROWTH
EUR 10 MILLION RAISED
* Offering oversubscribed 1.3 times
* 10 EUR million raised under the global placement and the open price offer
(OPO) after full exercise of the extension clause, which may be increased to
EUR 10.4 million in the event of exercise of the over-allotment option
* Final share price set at EUR3.84
* Start of trading on the Euronext Growth market on 10 July 2018
BIO-UV Group, a specialist in ultraviolet water treatment systems, announces
the success of its initial public offering on the Euronext Growth market in
Paris (ISIN code: FR0013345493/ Ticker: ALTUV).
In light of the strong demand, BIO-UV Group's Board of Directors today set the
final share price at EUR3.84.
It also decided to exercise the extension clause in full, enabling BIO-UV Group
to raise EUR10 million.
This figure could increase to EUR10.4 million if the over-allotment option is
Total demand came to 2,833,265 shares, including 87% under the global placement
(mainly intended for institutional investors) and 13% under the open price
offer (mainly intended for individual investors), such that the offering was
1.3 times oversubscribed(1).
The number of shares allocated under the global placement stands at 2,321,430
new shares, representing a total of EUR8,9 million. 375,380 shares were
allocated to the public under the open price offer, for an amount of EUR1.4
million. A1 and A2 orders will be 100% honoured.
The total number of shares issued following the full exercise of the extension
clause stands at 2,610,810 new shares. On these bases and given the IPO price
of EUR3.84 per share, BIO-UV Group has a market capitalisation of around EUR30
(1) Based on the initial offering: global placement and open price offer,
excluding the extension clause and over-allotment option.
Following this transaction, BIO-UV Group's share capital is composed of
7,789,295 shares. The company's free float accounts for 30.7% of its share
capital before the possible exercise of the over-allotment option.
BIO-UV Group has granted Gilbert Dupont an over-allotment option, exercisable
until 3 August 2018, for a maximum of 95,000 new shares, representing a maximum
amount of approximately EUR0.4 million.
Settlement/delivery of the new shares issued under the global placement and the
open price offer is scheduled for 09 July 2018. The shares will be admitted for
continuous trading on the Euronext Growth market as from 10 July 2018, under
the ISIN code: FR0013345493 and the ticker: ALTUV.
A liquidity contract will be implemented not later than the end of the
stabilisation period, which will start on 10 July 2018 and end on 3 August
2018. Its implementation will be announced to the market in due course, in
compliance with applicable legal and regulatory requirements.
On completion of the IPO, Benoit Gillmann, CEO and founder of BIO-UV Group,
commented: "We are proud to announce the success of our initial public offering
and would like to sincerely thank our reference shareholders (Soridec, Naxicap
and ACE Management) for their support, as well as all the new shareholders,
institutions and private individuals, who have put their faith in us. I would
also like to extend my warmest thanks to all the loyal employees of BIO-UV
Group, who, through their daily commitment, contribute to the company's success
in France and abroad since nearly 20 years. The funds raised will allow us to
accelerate our momentum and seize all opportunities that present themselves,
both on our historical markets and the ballast water treatment market, which is
set to see major growth."
Post-transaction breakdown of share ownership
Following the IPO, BIO-UV Group's share capital is distributed as follows:
Before issue of new shares
% of capital and
Shareholders Number of shares voting rights
(1) Including the double voting rights granted on the day of listing on the
Euronext Growth Paris market of the Company's shares.
(2) Company whose capital is wholly owned by Benoit GILLMANN, Chief Executive
Officer of the Company.
(3) ATALAYA is a Professional Private Equity Fund, represented by its
management company ACE MANAGEMENT.
Next steps in the transaction
09 July 2018 Settlement/delivery of new shares
10 July 2018 Start of trading on the Euronext Growth market in Paris
03 August 2018 Deadline for exercising the over-allotment option and
end of possible stabilisation period
About BIO-UV GROUP
Created in 2000, BIO-UV Group designs, manufactures and markets innovative
ultraviolet water treatment systems. The range of equipment developed by the
Group is aimed at several markets:
- The recreation market, on which BIO-UV Group is no. 1 in France and in Europe
for UV water treatment in residential swimming pools, and for the public and
semi-public community pool de-chlorination market;
- The municipal and industrial markets, on which specific ranges have been
developed for applications such as: purification, effluent treatment,
wastewater reuse, process waters, aquaculture, etc.;
- The ballast water treatment market, which has benefited since 2017 from a new
international regulation requiring all ships to have equipment to treat their
In 2017, BIO-UV Group generated revenue of EUR10.2 million and EBITDA of EUR1.1
million, representing an EBITDA margin of 11.1%. As of 31 March 2018, the Group
had 61 employees.
BIO-UV Group has been granted the "Innovative Company" label by Bpifrance and
is eligible for the French "PEA-PME" investment scheme.
+33 (0)4 99 13 39 11
The price of the open price offer and of the global placement is set at EUR3.84
Size of and gross proceeds from the offering
2,601,810 new shares were issued under the offering after full exercise of the
extension clause and before possible exercise of the over-allotment option.
Total gross proceeds from the issue stand at EUR10 million after the full
exercise of the extension clause and before the possible exercise of the
BIO-UV Group has granted Gilbert Dupont an over-allotment option, exercisable
from 10 July 2018 to 3 August 2018 2018 (inclusive), for a maximum of 95,000
new shares, or a maximum amount of EUR0.4 million.
Allotment of the offer
* Global placement: 2,321,430 shares were allocated to institutional investors,
or EUR8.9 million and approximately 86 % of the total shares offered;
* Open price offering: 375,380 shares were allocated to the public, or EUR1.4
million and approximately 14 % of the total shares offered (i.e. 17 % of the
initial offer before extension clause). A1 and A2 orders will be 100%
The Company's lock up commitment and shareholder retention commitments
* Company's lock-up agreement: 180 days from the date of settlement/delivery of
the new shares;
* Lock-up agreement applicable to all shareholders: 360 days from the date of
settlement/delivery of the new shares.
Listing Sponsor, Lead Arranger and Bookrunner
Characteristics of the shares
* Name: BIO-UV GROUP
* Ticker: ALTUV
* ISIN code: FR0013345493
* Listing market: Euronext Growth Paris
* ICB Classification: 2757 Industrial Machinery
* Eligible for PEA-PME and BPI Innovative Company qualification(2)
Availability of the Prospectus
Copies of the Prospectus, registered by the AMF on 22 June 2018 under number
18-255, are available free of charge on request from the registered office of
BIO-UV Group (850 avenue Louis Médard, 34400 Lunel) and on the websites of the
AMF (www.amf-france.org) and the Company (investir.bio-uv.com).
Any investment in shares entails some risk. The attention of investors is drawn
to Chapter 4 "Risk Factors" of Part One of the Prospectus approved by the
(2) These mechanisms are conditional and subject to the limit of available
caps. Interested parties should contact their financial advisor.
This press release and the information contained herein do not, and shall not,
in any circumstances constitute an offer to sell or purchase, or the
solicitation of an offer to sell or purchase BIO-UV Group shares in any
The dissemination, publication or distribution of this press release may, in
some countries, be subject to specific regulations. As a result, persons
physically present in these countries and in which the press release is
disseminated, published or distributed must inform themselves and comply with
these laws and regulations.
This press release constitutes a communication of a promotional nature and not
a prospectus within the meaning of Directive 2003/71/EC of the European
Parliament and of the Council of 4 November 2003 (as transposed in each of the
Member States of the economic Area European Union) (the "Prospectus
This document is not an offer of securities for sale nor the solicitation of an
offer to purchase securities in the United States of America. BIO-UV Group
shares or other securities may not be offered or sold in the United States of
America absent registration under the U.S. Securities Act of 1933, as amended
(the "Securities Act"), or an exemption from registration. The shares of the
company BIO-UV Group will be offered or sold only outside the United States of
America and in the context of offshore transactions, in accordance with
Regulation S of the Securities Act. Bio-UV Group does not intend to register
the offer in whole or in part in the United States of America or to make an
offer to the public in the United States of America.
With respect to the member States of the European Economic Area, which have
implemented the Prospectus Directive, no action has been undertaken or will be
undertaken to make an offer to the public of the securities referred to herein
requiring a publication of a prospectus in the context of a public offering in
any relevant member State other than France. As a result, the BIO-UV Group
shares may not and will not be offered in any relevant member State other than
France except in accordance with the exemptions set forth in Article 3(2) of
the Prospectus Directive, if they have been implemented in that relevant member
State, or under any other circumstances which do not require the publication by
BIO-UV Group of a prospectus in the context of a public offering pursuant to
Article 3 of the Prospectus Directive and/or to applicable regulations of that
relevant member State.
With respect to England, this press release is only being distributed to, and
is only directed at persons (i) who are not in the United Kingdom, (ii) are
"investment professionals" falling within Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the
"Order"), (iii) are persons falling within Article 49(2)(a) to (d) ("high net
worth companies, unincorporated associations, etc.") of the Order, or (iv) are
persons to whom an invitation or inducement to engage in investment activity
(within the meaning of Article 21 of the Financial Services and Markets Act
2000) in connection with the issue or sale of any securities may otherwise
lawfully be communicated or caused to be communicated directly or indirectly
(all such persons together being referred to as "Relevant Persons").
This document is directed only at Relevant Persons and must not be acted on or
relied on by persons who are not Relevant Persons.
This press release provides guidance on the objectives of BIO-UV Group and
contains prospective statements. This information is not historical data and
should not be construed as a guarantee that the facts and data set out will
occur. This information is based on data, assumptions and estimates considered
reasonable by BIO-UV Group. The latter operates in a competitive and rapidly
evolving environment. Therefore, BIO-UV Group is not in a position to
anticipate all risks, uncertainties or other factors likely to affect its
activity, their potential impact on its activity, or to what extent the
materialization of a risk or combination of risks could have significantly
different results from those mentioned in any prospective statements. This
information is only given on the date of this press release. BIO-UV Group makes
no commitment to publish updates to this information or the assumptions on
which it is based, with the exception of any legal or regulatory obligation
applicable to it.
No copy of this press release is, and shall be, distributed or sent directly or
indirectly to the United States of America, Canada, Japan or Australia.